BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), today announced that the Singapore Health Sciences Authority (HSA) has issued interim authorization for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Accuray Incorporated (NASDAQ: ARAY) announced today that Royal has selected two Radixact Systems with ClearRT™ helical fan-beam kVCT imaging and Synchrony® artificial intelligence (AI)-driven four-dimensional (4D) dynamic delivery technology to expand access to potentially life-saving radiotherapy treatments to more patients.

Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, announces its financial results for the fiscal year ended October 31, 2021 and provides a business update.

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its second quarter fiscal year ended December 31, 2021.

Murata Electronics North America, Inc., a wholly owned subsidiary of Murata Manufacturing Co., Ltd., and Resonant Inc. (Resonant) (NASDAQ: RESN) today announced that they have entered into a definitive agreement under which Murata will acquire all outstanding shares of Resonant not owned by Murata for $4.50 per share in cash.

Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received LUMAKRAS® (sotorasib)*.

OnQuality Pharmaceuticals (“OnQuality”), today announced it will be presenting two posters on Hand-Foot Skin Reaction (HFSR), including a Trial in Progress on its NOVA-II Phase 2 study and the results of an oncologist survey, at the American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO GU).

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC).

Today Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) announced two-year (25.4 months minimum; 32.9 months median) follow-up results from analyses of the Phase 3 CheckMate -9ER trial, demonstrating sustained survival and response rate benefits, as well as health-related quality of life (HRQoL) improvements, with the combination of Opdivo® (nivolumab) and CABOMETYX®.

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU-011, which is being developed for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).